These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Hiatt WR; Bonaca MP; Patel MR; Nehler MR; Debus ES; Anand SS; Capell WH; Brackin T; Jaeger N; Hess CN; Pap AF; Berkowitz SD; Muehlhofer E; Haskell L; Brasil D; Madaric J; Sillesen H; Szalay D; Bauersachs R Circulation; 2020 Dec; 142(23):2219-2230. PubMed ID: 33138628 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rivaroxaban compared with warfarin in patients undergoing peripheral arterial procedures. Talukdar A; Wang SK; Czosnowski L; Mokraoui N; Gupta A; Fajardo A; Dalsing M; Motaganahalli R J Vasc Surg; 2017 Oct; 66(4):1143-1148. PubMed ID: 28712814 [TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. Wheeler M; Chan N; Eikelboom J Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment. Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167 [TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection? Bauersachs R; Zannad F Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413 [TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in Peripheral Artery Disease after Revascularization. Ultee KHJ; Steunenberg SL; Schouten O N Engl J Med; 2020 Nov; 383(21):2089-2090. PubMed ID: 33207107 [No Abstract] [Full Text] [Related]
16. Rivaroxaban in Peripheral Artery Disease after Revascularization. Gremmel T N Engl J Med; 2020 Nov; 383(21):2090. PubMed ID: 33207108 [No Abstract] [Full Text] [Related]
17. Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply. Bonaca MP; Bauersachs RM; Hiatt WR N Engl J Med; 2020 Nov; 383(21):2090-2091. PubMed ID: 33207109 [No Abstract] [Full Text] [Related]
18. Pharmacological management of obstructive peripheral arterial disease: two case reports. Détriché G; Lanéelle D; Radureau C Hosp Pract (1995); 2021 Dec; 49(5):379-383. PubMed ID: 34278930 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113 [TBL] [Abstract][Full Text] [Related]
20. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]